Blood Transfusion - 6 2020 (November-December)
Transfusion-transmitted cytomegalovirus: ehaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland
 
Authors:  Sophie Voruz, Peter Gowland, Claudia Eyer, Nadja Widmer, Mélanie Abonnenc, Michel Prudent, Stavroula Masouridi-Levrat, Michel A. Duchosal, Christoph Niederhauser
Pages:  446-453
To cite this article:  Blood Transfus 2020; 18: 446-53
Doi:  10.2450/2020.0241-19
Published online:  28/02/2020

Preview
ABSTRACT

Background.
Nowadays, most blood products are leukocyte-reduced. After this procedure, the residual risk for transfusion transmitted cytomegalovirus (TT-CMV) is mostly attributed to cell-free viruses in the plasma of blood donors following primary infection or viral reactivation. Here, objectives are: 1) to study the behaviour of cell-free CMV through the blood component processing; 2) to determine the anti-CMV seroprevalence, the level of viremia, the window-period in blood donor population; and 3) to identify cases of
TT-CMV in bone marrow transplant (BMT) recipients.
Materials and methods. Cell-free CMV was injected into blood bags originating from regular donors. Blood components were processed according to either the CompoSelect® or the CompoFlow® (Fresenius Kabi AG) techniques. Samples were analysed at each step for presence of virus DNA using quantitative polymerase chain reaction (PCR). The anti-CMV seroprevalence in our donor population was taken from our donor data system. The viremia was assessed in pooled plasmas samples from routine donations by quantitative PCR. Medical charts of 165 BMT anti-CMV seronegative recipients/anti-CMV seronegative donors who received CMV-unscreened blood products were reviewed.
Results. Cell-free CMV passes without any decrease in viral load through all stages of blood processing. The anti-CMV seroprevalence was 46.13%. Four DNA positive samples out of 42,240 individual blood donations were identified (0.009%); all had low levels of viremia (range 11-255 IU/mL). No window-period donation was identified. No TT-CMV was found.
Discussion. Cell-free CMV remains a concern with current blood component processing as it passes through all the processes. However, since low levels of CMV DNA were identified in the donations tested, and no BMT recipients had TT-CMV, the residual threat of TT-CMV after leukocyte reduction appears to be very low.
 
Keywords: cytomegalovirus, cell free virus, blood components, transfusion-transmission.
 
  
Full Text Download Back
       
Share this article: